奥莱扎森是一种肝脏导向的APOC3ASO疗法,用于治疗高甘油三血症
Amanda J Hooper1,2, Damon A Bell1,2,3, John R Burnett1,2
1Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital & Fiona Stanley Hospital Network, Perth, Western Australia, Australia.
Expert opinion on pharmacotherapy
|September 21, 2024
概括
奥莱萨森是一种反感性寡核酸,有效降低过高甘油三血症患者的甘油三水平. 目前正在进行的试验将确定其降低心血管疾病风险的潜力.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 心血管疾病 心血管疾病
- 遗传学 是一个遗传学.
背景情况:
- 脂蛋白 (apo) C-III 是血甘油三化物 (TG) 水平的关键调节剂.
- 过高甘油三血症 (HTG) 会增加胰腺炎和动脉样硬化心血管疾病 (ASCVD) 的风险.
研究的目的:
- 讨论apoc-III作为HTG的治疗点.
- 描述olezarsen的药理动力学,药理动力学和新陈代谢.
- 报告对olezarsen的临床试验结果,一个肝脏导向的APOC3反感性寡核酸 (ASO).
主要方法:
- 对olezarsen的临床试验数据的审查.
- 对olezarsen在降低TG水平方面的有效性的分析.
- 对olezarsen的安全性概况的评估,包括肝酶和血小板缺血.
主要成果:
- 在极度和中度高血压患者中,olezarsen可将TG水平降低约50%.
- 奥莱扎森不会导致肝酶或血小板缺血的临床意义上的升高.
- 目前正在进行的第三期试验 (CORE,CORE2,ESSENCE) 将提供进一步的见解.
结论:
- 奥莱扎森是一种有前途的HTG治疗药物,向apoC-III.
- 需要进一步的研究来证实其ASCVD风险降低的好处.
- 即将到来的试验结果将指导未来的心血管结局试验.
关键词:
在APOC3中使用APOC3.在ASO的基础上,ASO是ASO.在 ApoC-III 中.这是一种ApoC-III抑制剂.心血管疾病心血管疾病过高甘油三糖血症的发生.这是Olezarsen的作品.胰腺炎是一种炎症.更多相关视频
04:26Efficient Gene Knockdown in the Liver via Intrasplenic Injection of Adeno-Associated Virus Serotype 8 (AAV8)-Delivered Small Hairpin RNA
Published on: November 1, 2024
299
19:02High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
Published on: March 22, 2011
13.3K
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
584
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
584
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
167
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
167
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170